If hot flashes, broken sleep, and mood changes arrive together, it is natural to wonder whether they share one explanation and one treatment. A new ACOG guideline takes a more careful approach: it looks at these concerns together while distinguishing the evidence for each. That distinction is the most useful part of the news.
What ACOG has published
The American College of Obstetricians & Gynecologists has published Clinical Practice Guideline No. 13, Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms, in the November 2026 issue of Obstetrics & Gynecology. It replaces Practice Bulletin No. 141 from January 2014. This is an evidence-based professional guideline, rather than a new treatment trial. ACOG guideline, opening page.
Its scope includes perimenopausal and postmenopausal people with symptoms related to spontaneous menopause or induced menopause at or beyond age 40. Other topics, including premature ovarian insufficiency and osteoporosis management, are addressed in separate documents. The guideline therefore answers a defined set of symptom questions, rather than every question about midlife health. Scope, pages e345–e346.
Hot flashes and sleep: a specific connection
ACOG gives a strong recommendation, supported by moderate-quality evidence, for systemic menopausal hormone therapy for vasomotor symptoms in people without contraindications. Vasomotor symptoms means hot flashes and night sweats. A separate recommendation addresses sleep disruption related to those symptoms. The document distinguishes estrogen alone, when endometrial protection is not needed, from estrogen with a progestogen for people with a uterus. Summary of recommendations, page e346.
The sleep wording matters. For example, someone might be waking during night sweats and wondering whether the sleep problem belongs in the same conversation. That is a more specific question than asking whether hormones explain every difficult night. Our hormones and sleep guide provides background on that broader topic.
Mood is not treated as an interchangeable symptom
The guideline finds insufficient evidence to recommend for or against estrogen-only or estrogen–progestogen therapy specifically for menopause-related depressive symptoms. It directs clinicians to depression-management guidance when major depressive disorder criteria are met or depression is the predominant symptom. It also covers nonhormonal medicines and nonmedication approaches, with recommendations of different strengths. Recommendations, pages e346–e347.
This leaves room for a more precise discussion. “My sleep is interrupted by sweating” and “My main concern is depression” are different descriptions of what someone wants help understanding. Neither has to be dismissed simply because several symptoms overlap.
What the recommendation labels mean
The writing group used a modified GRADE framework to assess evidence and develop recommendations. Strength and evidence quality are separate labels. For example, the recommendation about timing of hormone therapy is strong but rests on low-to-moderate-quality evidence. The guideline also includes ungraded good-practice points where formal evidence is limited. Those labels help show how a conclusion was reached; they are not a personal eligibility score. Methods and recommendation development, pages e347–e348.
What it means at different life stages
The guideline places age, medical history, symptom priorities, and baseline risks in a shared decision-making discussion. It does not make a treatment suitable for everyone of a certain age. For younger readers, its stated age and symptom scope also matters: a menopause headline cannot automatically explain a different life-stage concern. Our perimenopause and menopause comparison explains the terminology.
Questions for your healthcare provider
- Which of my concerns falls within this guideline’s scope?
- Is my sleep concern connected with night sweats, or does it need a different explanation?
- What evidence applies specifically to mood symptoms in my situation?
- How do my medical history and priorities affect the discussion?
Sources
- Clinical Practice Guideline No. 13 — ACOG, Obstetrics & Gynecology, November 2026, 148:e345–e369. Full guideline reviewed.
This article is for educational purposes and isn’t medical advice. Talk to your healthcare provider about your situation.
